Applications: |
WB |
Note: |
STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS. |
Short Description: |
UBR1 Positive Control for STJ503454 is synthetically produced from the sequence and is suitable for use in western blot applications. |
Formulation: |
Provided as 100 uL ready-to-use, in SDS-PAGE sample buffer (Laemelli's buffer) containing Tris, pH 6.8, 1 % SDS, Glycerol and Bromophenolblue blue as tracking dye. The sample is reduced by adding 2% beta mercaptoethanol. The protein concentration is |
Dilution Range: |
WB: 1:500 |
Storage Instruction: |
Store at-20°C for long term storage. Avoid freeze-thaw cycles. |
Gene Symbol: |
UBR1 |
Gene ID: |
197131 |
Uniprot ID: |
UBR1_HUMAN |
Specificity: |
This is positive control is recommended for use in combination with UBR1 antibody STJ503454. |
Tissue Specificity | Broadly expressed, with highest levels in skeletal muscle, kidney and pancreas. Present in acinar cells of the pancreas (at protein level). |
Function | E3 ubiquitin-protein ligase which is a component of the N-end rule pathway. Recognizes and binds to proteins bearing specific N-terminal residues that are destabilizing according to the N-end rule, leading to their ubiquitination and subsequent degradation. May be involved in pancreatic homeostasis. Binds leucine and is a negative regulator of the leucine-mTOR signaling pathway, thereby controlling cell growth. |
Peptide Name | E3 Ubiquitin-Protein Ligase Ubr1N-Recognin-1Ring-Type E3 Ubiquitin Transferase Ubr1Ubiquitin-Protein Ligase E3-Alpha-1Ubiquitin-Protein Ligase E3-Alpha-I |
Database Links | Reactome: R-HSA-983168 |
Cellular Localisation | CytoplasmCytosol |
Alternative Peptide Names | E3 Ubiquitin-Protein Ligase Ubr1 proteinN-Recognin-1 proteinRing-Type E3 Ubiquitin Transferase Ubr1 proteinUbiquitin-Protein Ligase E3-Alpha-1 proteinUbiquitin-Protein Ligase E3-Alpha-I proteinUBR1 protein |
Information sourced from Uniprot.org
12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance